Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGB-23339 · 1 trial · 1 indication
Vital signs include blood pressure and pulse rate
Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis
| Arm | Type | Description |
|---|---|---|
| Part A Dose Escalation (Single Ascending Dose) | EXPERIMENTAL | Up to 5 dose levels of BGB-23339 or Placebo |
| Part B Dose Escalation (Multiple Ascending Dose) | EXPERIMENTAL | Up to 4 dose levels of BGB-23339 or placebo based on data collected in Part A |
| Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study) | EXPERIMENTAL | Up to 2 dose levels of BGB-23339 or placebo based on data collected in Part A and B (conducted in China only) |
| Part D (Food-Effect Study) | EXPERIMENTAL | Three single dose levels of BGB-23339 under different feeding conditions |
| Name | Type | Description |
|---|---|---|
| BGB-23339 | DRUG | Administered orally as a tablet |
| Placebo | DRUG | Administered orally as a tablet |
Inclusion Criteria: 1. Signed informed consent form (ICF) and able to comply with study requirements 2. Healthy men and/or women of no childbearing potential of age ≥ 18 years and ≤ 55 years on the day of signing the ICF (or the legal age of consent) for Parts A, B and D; of age≥ 18 years and ≤ 45 ...
BGB-23339 is an investigational small molecule being developed by BeOne Medicines Ltd. (ticker: ONC). It is currently in Phase 1 clinical development. The specific indication for BGB-23339 has not been determined, and it is being studied in healthy volunteers.
BGB-23339 is being developed by BeOne Medicines Ltd., a biopharmaceutical company listed under the ticker ONC. The company is conducting clinical trials for this investigational small molecule, which is currently in Phase 1 development.
BGB-23339 is in Phase 1 clinical development. A first-in-human study has been completed, which evaluated single- and multiple-ascending doses and the effect of food in healthy participants. The drug remains investigational and is not yet approved for any use.
BGB-23339 has one completed clinical trial, identified as NCT05093270. This was a first-in-human, single- and multiple-ascending dose and food-effect study conducted in healthy participants. The trial enrolled 92 participants and took place in Australia and China.
BGB-23339 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A first-in-human study has been completed, but the drug has not yet received regulatory approval for any indication.